+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

  • ID: 3629532
  • Report
  • February 2016
  • Region: Global
  • 32 Pages
  • La Merie Publishing
Three Different PTH Receptor Agonists Had Been Approved for Treatment of Women and Men at High Risk for Osteoporosis or Hypoparathyroidism, the Three Products Achieved Combined Sales of US$ 1.6 Billion in 2015
This Competitive Intelligence report titled "PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors" provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis or of hypoparathyroidism as of February 2016.

As of 2015, three different PTH receptor agonists had been approved for treatment of women and men at high risk for osteoporosis or hypoparathyroidism. The three products achieved in 2015 combined sales of US$ 1.6 bln. The forthcoming patent expiry of teriparatide, the relatively easy production in E.coli and blockbuster sales make teriparatide an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products.

This report evaluates current R&D activities for improved PTH-R agonists based on drug delivery solutions or molecular variation and on biosimilar products and developments in regulated and in less regulated markets. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication
- R&D Stage

About Competitor Analysis Series:

The Competitor Analysis Series delivers no-frills, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Note: Product cover images may vary from those shown
1. Marketed 1st Generation, Branded PTH Receptor Agonists

2. Drug Delivery Solutions for PTH Receptor Agonists:
- Nasal
- Oral
- Transdermal

3. Molecularly-Defined Teriparatide Biosuperiors

4. Teriparatide Biosimilars
- In Regulated Markets
- In Less Regulated Markets

5. Corporate PTH Agonist Biosimilars & Biosuperiors R&D Pipelines
Note: Product cover images may vary from those shown